University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Michael Evans, PhD

Michael Evans, PhD

Assistant Professor in Residence, Department of Radiology and Biomedical Imaging, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

The central aim of my lab’s research is to develop novel biomarkers to non-invasively measure oncogene activity in cancer to improve diagnosis and the assessment of drug pharmacodynamics. This is a highly interdisciplinary research program, and I recruit students and postdocs that generally have a specialized background (i.e. a strong training in organic chemistry or cell biology, but not both), and train them in the other areas required of a well round molecular imaging researcher. Our projects span all aspects of biomarker development, from discovery with “omic” technologies, to refinement of lead agents to improve bioactivity in vivo. The majority of our de novo radiotracer development focuses on small molecule organic chemistry, and our antibody radiotracer development programs involves new bioconjugation chemistry, and defining and exploiting the biological mechanisms that underwrite the aberrant expression of cell surface receptors in cancer.

Education

St. Mary’s College of Maryland, MD, BA, 2001, Chemistry
The Scripps Research Institute, La Jolla, CA, PhD, 2007, Chemical Biology
Memorial Sloane Kettering Cancer Center, New York, NY, Postdoctoral, 2013, Molecular Imaging, Cancer Biology


Professional Experience

  • 2013-2013
    Senior Research Scientist, Human Oncology and Pathogenesis Program, MSKCC
  • 2013-present
    Assistant Professor in Residence, Department of Radiology and Biomedical Imaging, UCSF

Honors & Awards

  • 2005
    1st Place Presentation, TSRI Faculty-Student Retreat
  • 2007-2010
    R25T Fellowship, National Institutes of Health (administered via MSKCC)
  • 2011-2012
    Research Grant, Brain Tumor Center, MSKCC
  • 2012
    Pathway to Independence Award, NCI
  • 2012-2014
    Research Grant, Imaging and Radiation Sciences Bridge Program, MSKCC
  • 2013
    Poster Award, World Molecular Imaging Congress, Savannah, GA
  • 2013
    David H. Koch Young Investigator Award, Prostate Cancer Foundation

Selected Publications

  1. Flavell RR, Evans MJ, Villanueva-Meyer JE, Yom SS. Understanding response to immunotherapy using standard of care and experimental imaging approaches. Int J Radiat Oncol Biol Phys. 2020 Jun 22.
    View on PubMed
  2. Moroz A, Wang YH, Sharib JM, Wei J, Zhao N, Huang Y, Chen Z, Martinko AJ, Zhuo J, Lim SA, Zhang LH, Seo Y, Carlin S, Leung KK, Collisson EA, Kirkwood KS, Wells JA, Evans MJ. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clin Cancer Res. 2020 Apr 27.
    View on PubMed
  3. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Blecha JE, VanBrocklin HF, Seo Y, Sayeed M, Feldman BJ, Aggarwal R, Behr SC, Shao H, Wilson DM, Villanueva-Meyer JE, Gestwicki JE, Evans MJ. A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chem Biol. 2020 Jun 19; 15(6):1381-1391.
    View on PubMed
  4. Kalita M, Parker MFL, Luu JM, Stewart MN, Blecha JE, VanBrocklin HF, Evans MJ, Flavell RR, Rosenberg OS, Ohliger MA, Wilson DM. Arabinofuranose-derived positron-emission tomography radiotracers for detection of pathogenic microorganisms. J Labelled Comp Radiopharm. 2020 May 15; 63(5):231-239.
    View on PubMed
  5. Seo Y, Khalighi MM, Wangerin KA, Deller TW, Wang YH, Jivan S, Kohi MP, Aggarwal R, Flavell RR, Behr SC, Evans MJ. Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. Mol Imaging Biol. 2020 02; 22(1):208-216.
    View on PubMed
  6. Wei J, Leung K, Truillet C, Ruggero D, Wells JA, Evans MJ. Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling. Mol Cell Proteomics. 2020 02; 19(2):294-307.
    View on PubMed
  7. Wang S, Blaha C, Santos R, Huynh T, Hayes TR, Beckford-Vera DR, Blecha JE, Hong AS, Fogarty M, Hope TA, Raleigh DR, Wilson DM, Evans MJ, VanBrocklin HF, Ozawa T, Flavell RR. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy. Mol Pharm. 2019 09 03; 16(9):3831-3841.
    View on PubMed
  8. Muir RK, Zhao N, Wei J, Wang YH, Moroz A, Huang Y, Chen YC, Sriram R, Kurhanewicz J, Ruggero D, Renslo AR, Evans MJ. Measuring Dynamic Changes in the Labile Iron Pool in Vivo with a Reactivity-Based Probe for Positron Emission Tomography. ACS Cent Sci. 2019 Apr 24; 5(4):727-736.
    View on PubMed
  9. Drake CR, Evans MJ, VanBrocklin HF. Enzymatically Catalyzed Radiofluorination of Biomolecules. Methods Mol Biol. 2019; 2033:191-205.
    View on PubMed
  10. Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, Chen M, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, Bousquet P, Mankovich J, Kingsbury G, Fong L. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Invest. 2019 01 02; 129(1):349-363.
    View on PubMed
  11. Behr SC, Villanueva-Meyer JE, Li Y, Wang YH, Wei J, Moroz A, Lee JK, Hsiao JC, Gao KT, Ma W, Cha S, Wilson DM, Seo Y, Nelson SJ, Chang SM, Evans MJ. Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight. 2018 11 02; 3(21).
    View on PubMed
  12. Moroz A, Lee CY, Wang YH, Hsiao JC, Sevillano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ. A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4. Bioconjug Chem. 2018 10 17; 29(10):3476-3482.
    View on PubMed
  13. Henry KE, Dacek MM, Dilling TR, Caen JD, Fox IL, Evans MJ, Lewis JS. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clin Cancer Res. 2019 01 01; 25(1):166-176.
    View on PubMed
  14. Lux F, Tran VL, Thomas E, Dufort S, Rossetti F, Martini M, Truillet C, Doussineau T, Bort G, Denat F, Boschetti F, Angelovski G, Detappe A, Crémillieux Y, Mignet N, Doan BT, Larrat B, Meriaux S, Barbier E, Roux S, Fries P, Müller A, Abadjian MC, Anderson C, Canet-Soulas E, Bouziotis P, Barberi-Heyob M, Frochot C, Verry C, Balosso J, Evans M, Sidi-Boumedine J, Janier M, Butterworth K, McMahon S, Prise K, Aloy MT, Ardail D, Rodriguez-Lafrasse C, Porcel E, Lacombe S, Berbeco R, Allouch A, Perfettini JL, Chargari C, Deutsch E, Le Duc G, Tillement O. AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br J Radiol. 2019 Jan; 92(1093):20180365.
    View on PubMed
  15. Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2045-2054.
    View on PubMed
  16. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):78-82.
    View on PubMed
  17. Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018 05 02; 10(439).
    View on PubMed
  18. C. Truillet, N. Sevillano, B. Jego, E. Jaumain, C. Craik, C.I. Wang, M. Evans. PET imaging of tumor PD-L1 expression with 89Zr-labeled anti-PD-L1 antibodies. Nuklearmedizin. 2018 May 1; 42(3):158.
    View on PubMed
  19. Truillet C, Parker MFL, Huynh LT, Wei J, Jami KM, Wang YH, Shen YS, Sriram R, Wilson DM, Kurhanewicz J, Evans MJ. Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget. 2018 Apr 17; 9(29):20399-20408.
    View on PubMed
  20. Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA. Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife. 2018 01 23; 7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI